<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">33059460</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>09</Month>
        <Day>06</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>01</Month>
        <Day>05</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1440-1614</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>55</Volume>
            <Issue>8</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Aug</Month>
            </PubDate>
          </JournalIssue>
          <Title>The Australian and New Zealand journal of psychiatry</Title>
          <ISOAbbreviation>Aust N Z J Psychiatry</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Quetiapine withdrawal: A systematic review.</ArticleTitle>
        <Pagination>
          <StartPage>772</StartPage>
          <EndPage>783</EndPage>
          <MedlinePgn>772-783</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1177/0004867420965693</ELocationID>
        <Abstract>
          <AbstractText Label="OBJECTIVE">Withdrawal from psychoactive medication such as quetiapine is a well-documented phenomenon. Despite the extensive use of quetiapine, there have been few studies into the presence of discontinuation symptoms. We therefore performed a systematic review of published literature for evidence of quetiapine withdrawal or symptoms associated with discontinuation.</AbstractText>
          <AbstractText Label="METHODS">We searched PubMed, Embase, CINAHL, Medline, Web of Science, PsycINFO for articles containing the terms 'Quetiapine' AND 'withdraw<sup>$</sup>' OR 'discontinue<sup>$</sup>'. We included all study types that reported on somatic withdrawal symptoms and had no language restrictions. We excluded studies where there was withdrawal from multiple medications or any other psychoactive substance, or where the only symptoms were psychological such as rebound psychosis or craving.</AbstractText>
          <AbstractText Label="RESULTS">We included 13 papers, all of which were individual case reports. The quality of the individual case reports was sub-optimal, as assessed by the CARE Case Report Guidelines. There was an association between rapid cessation of quetiapine and onset of somatic symptoms such as nausea, vomiting, agitation, restlessness, diaphoresis, irritability, anxiety, dysphoria, sleep disturbance, insomnia, tachycardia, hypertension and dizziness. Three studies also reported the onset of a withdrawal dyskinesia characterised by abnormal choreiform movements as well as confusion and speech disturbance in some cases. However, these findings were limited by the number and quality of case reports identified.</AbstractText>
          <AbstractText Label="CONCLUSION">Discontinuation symptoms are an uncommon side effect of quetiapine cessation, which may have clinical implications. Clinicians should therefore be alert to the possibility of quetiapine withdrawal in individuals who present with somatic symptoms or choreiform movements. However, large prospective studies are required to clarify this association.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Monahan</LastName>
            <ForeName>Katherine</ForeName>
            <Initials>K</Initials>
            <Identifier Source="ORCID">0000-0002-7833-5922</Identifier>
            <AffiliationInfo>
              <Affiliation>Metro South Addiction and Mental Health Services, Woolloongabba, QLD, Australia.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Faculty of Medicine, The University of Queensland, Woolloongabba, QLD, Australia.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>West Moreton Health, Ipswich, QLD, Australia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cuzens-Sutton</LastName>
            <ForeName>Jaimie</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>School of Nursing, Midwifery and Social Work, The University of Queensland, Woolloongabba, QLD, Australia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Siskind</LastName>
            <ForeName>Dan</ForeName>
            <Initials>D</Initials>
            <Identifier Source="ORCID">0000-0002-2072-9216</Identifier>
            <AffiliationInfo>
              <Affiliation>Metro South Addiction and Mental Health Services, Woolloongabba, QLD, Australia.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Faculty of Medicine, The University of Queensland, Woolloongabba, QLD, Australia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kisely</LastName>
            <ForeName>Steve</ForeName>
            <Initials>S</Initials>
            <Identifier Source="ORCID">0000-0003-4021-2924</Identifier>
            <AffiliationInfo>
              <Affiliation>Metro South Addiction and Mental Health Services, Woolloongabba, QLD, Australia.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Faculty of Medicine, The University of Queensland, Woolloongabba, QLD, Australia.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>West Moreton Health, Ipswich, QLD, Australia.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D002363">Case Reports</PublicationType>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D000078182">Systematic Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>10</Month>
          <Day>16</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Aust N Z J Psychiatry</MedlineTA>
        <NlmUniqueID>0111052</NlmUniqueID>
        <ISSNLinking>0004-8674</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>2S3PL1B6UJ</RegistryNumber>
          <NameOfSubstance UI="D000069348">Quetiapine Fumarate</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <CommentsCorrectionsList>
        <CommentsCorrections RefType="CommentIn">
          <RefSource>Aust N Z J Psychiatry. 2022 Jan;56(1):98</RefSource>
          <PMID Version="1">33971722</PMID>
        </CommentsCorrections>
      </CommentsCorrectionsList>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D001008" MajorTopicYN="N">Anxiety Disorders</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011595" MajorTopicYN="N">Psychomotor Agitation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011618" MajorTopicYN="Y">Psychotic Disorders</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000069348" MajorTopicYN="N">Quetiapine Fumarate</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013375" MajorTopicYN="Y">Substance Withdrawal Syndrome</DescriptorName>
          <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">Quetiapine</Keyword>
        <Keyword MajorTopicYN="Y">discontinuation</Keyword>
        <Keyword MajorTopicYN="Y">discontinuation symptoms</Keyword>
        <Keyword MajorTopicYN="Y">withdrawal</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>10</Month>
          <Day>17</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>7</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>10</Month>
          <Day>16</Day>
          <Hour>5</Hour>
          <Minute>32</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33059460</ArticleId>
        <ArticleId IdType="doi">10.1177/0004867420965693</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
